Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608777 · ClinicalTrials.gov registry record · Phase 4
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
A Phase 4 study, sponsored by Derm Research, PLLC.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00608777: Clinical Trial Phase 4 study, sponsored by Derm Research, PLLC.
NCT00608777 is a Phase 4 study that was terminated before completion, run by Derm Research, PLLC. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608777, a Phase 4 study, was terminated before completion, sponsored by Derm Research, PLLC.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Taclonex) could be used to manage LMB and thus allow patients to continue efalizumab without interruption.
Interventions
- DRUG Calcipotriene/betamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Why NCT00608777 stopped before completion
NCT00608777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Calcipotriene/betamethasone is the first listed.
NCT00608777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00608777 about?
NCT00608777 is a clinical study titled "Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)". The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe plaque psoriasis. It is hypothesized that calcipotriene/betamethasone (Tac...
What is the current status of trial NCT00608777?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2008-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00608777?
The interventions under investigation include: Calcipotriene/betamethasone (DRUG).
Who is sponsoring clinical trial NCT00608777?
This trial is sponsored by Derm Research, PLLC, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00608777's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia